BrainStorm Secures $400K in Premium Private Placements, Bolstering Critically Low Cash
BCLI sits 50% above its 52-week low of $0.459.
Summary
BrainStorm Cell Therapeutics has announced it secured an aggregate of $400,000 through private placements. This capital raise is particularly notable as the placements were priced at a premium to the market, indicating investor confidence or strategic interest. This financing directly addresses the company's critically low cash reserves of $15,000 and the explicit going concern warning reported in its recent 10-Q and 8-K filings on May 15, which also detailed a $2.1 million quarterly net loss. While the amount provides a crucial, immediate lifeline, the company will need to secure further funding to sustain operations given its burn rate.
At the time of this announcement, BCLI was trading at $0.69 on OTC in the Life Sciences sector, with a market capitalization of approximately $7.6M. The 52-week trading range was $0.46 to $1.92. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.